In support of Dr. Baldassano’s talk (NASPGHAN17: Treat to Target and Tight Control), this poster from the Cincinnati group (A Mulgand et al) showed that therapeutic drug monitoring has been associated with improved clinical remission scores (80% to 87%). Correlation with a more objective marker of remission along with longer followup is now needed. One of the authors, Dana Dykes, has joined our group in Atlanta!
Related blog posts:
- AGA Guidelines on Therapeutic Drug Monitoring
- What you might not know about anti-TNF monitoring …
- Preemptive Drug Monitoring –Not That Helpful
- “Silent” Crohn’s Disease | gutsandgrowth
- CCFA Conference Notes 2014 (part 1) | gutsandgrowth
- Treating to Target | gutsandgrowth
- New Target Drug Levels in Inflammatory Bowel Disease | gutsandgrowth
gutsandgrowth 